

[Coding Implications](#)  
[Revision log](#)

# CONCERT INFECTIOUS DISEASE: VECTOR-BORNE AND TROPICAL DISEASES TESTING

---

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

## OVERVIEW

Vector-borne diseases are caused by bacteria, viruses, and parasites that are transmitted by other living organisms to humans. Mosquitos, fleas, and ticks are examples of vectors. Mosquitoes can transmit diseases such as malaria or Zika virus infection, and ticks can transmit Lyme disease and ehrlichiosis, among others. Risk factors for vector-borne diseases include geographical area/climate, seasonality, quality of water supply and sanitation, and social factors influencing contact with vectors, such as travel and trade. Many vector-borne illnesses are most common in tropical or subtropical environments. This policy outlines coverage criteria for Lyme disease and Zika virus testing via serologic and molecular methods.

This policy is intended for use in the outpatient setting.

## POLICY REFERENCE TABLE

<u>Criteria Sections</u>	<u>Example Tests (Labs)</u>	<u>Ref</u>
<a href="#">Lyme Disease (<i>Borrelia burgdorferi</i>) Serum Antibody Tests</a>	Lyme Disease Ab with Reflex to Blot (IgG, IgM) (Quest Diagnostics)	1
<a href="#">Lyme Disease (<i>Borrelia burgdorferi</i>) Nucleic Acid/PCR Tests</a>	Lyme Disease, <i>Borrelia burgdorferi</i> , Real-time PCR (LabCorps)	
<a href="#">Other Non-covered Lyme Disease Tests</a>	Lymphocyte Antigen Proliferation (ARUP Laboratories)	
	Lyme Borrelia Nanotrap Urine Antigen Test (Galaxy Diagnostics)	
	Lyme ImmunoBlots IgG (IGeneX Inc.) Lyme ImmunoBlot IgM (IGeneX Inc.)	
<a href="#">Zika Virus Nucleic Acid/PCR Tests</a>	Zika Virus, PCR, Molecular Detection, Serum (Mayo Clinic Laboratories)	2, 3
<a href="#">Zika Virus Antibody Tests</a>	Zika Virus, IgM Antibody Capture ELISA, Serum (Mayo Clinic Laboratories)	

## CRITERIA

It is the policy of health plans affiliated with Centene Corporation® that the specific tests noted below are **medically necessary** when meeting the related criteria:

### LYME DISEASE TESTS

#### Lyme Disease (*Borrelia burgdorferi*) Serum Antibody Tests

- I. Lyme disease serum antibody testing is considered **medically necessary** when:
  - A. The member/enrollee had a plausible exposure to *Borrelia burgdorferi*, **AND**

- B. The member/enrollee has at least one of the following:
1. Skin lesion(s) suggestive of, but atypical for erythema migrans, **OR**
  2. Suspected [Lyme neuroborreliosis](#) involving either the peripheral or central nervous system, **OR**
  3. Suspected [Lyme arthritis](#), **OR**
  4. Acute myocarditis/pericarditis.
- II. Current evidence does not support the use of Lyme disease serum antibody testing for all other indications, including:
- A. Asymptomatic patients following tick bite
  - B. Erythema migrans
  - C. Typical amyotrophic lateral sclerosis
  - D. Relapsing-remitting multiple sclerosis
  - E. Parkinson's disease
  - F. Dementia/cognitive decline
  - G. New-onset seizures
  - H. Nonspecific magnetic resonance imaging (MRI) white matter abnormalities confined to the brain
  - I. Psychiatric illness
  - J. Children presenting with developmental or behavioral disorders
  - K. Chronic cardiomyopathy of unknown cause.

[back to top](#)

### **Lyme Disease (*Borrelia burgdorferi*) Nucleic Acid/PCR Tests**

- I. Lyme disease nucleic acid/PCR testing is considered **medically necessary** when:
- A. The member/enrollee is seropositive for Lyme disease, **AND**
  - B. The member/enrollee suspected [Lyme arthritis](#), **AND**
  - C. This testing is necessary for making treatment decisions.

- II. Current evidence does not support the use of Lyme disease nucleic acid/PCR testing for all other indications, including:
  - A. For the purpose of diagnosing Lyme disease.

[back to top](#)

## Other Non-covered Lyme Disease Tests

- I. Current evidence does not support the use of these specific Lyme disease tests:
  - A. Lymphocyte transformation tests
  - B. Lyme Borrelia Nanotrap Urine Antigen Test
  - C. Lyme ImmunoBlots IgG
  - D. Lyme ImmunoBlot IgM

[back to top](#)

## ZIKA TESTS

### Zika Virus Nucleic Acid/PCR Tests

- I. Zika virus nucleic acid/PCR tests are considered **medically necessary** when:
  - A. The member/enrollee is pregnant, **AND**
    - 1. Had a plausible exposure to Zika virus (e.g., traveled to or lives in an area with transmission or sexual relations with someone who traveled to or lives in an area with transmission), **OR**
  - B. The member/enrollee is 12 months of age or younger, **AND**
    - 1. The member's/enrollee's mother had laboratory evidence of Zika virus infection during pregnancy, **OR**
    - 2. Has [symptoms of congenital Zika virus infection](#), **AND**
      - a) The member's/enrollee's mother had a plausible exposure to Zika virus (regardless of mother's Zika virus test results).

- II. Current evidence does not support the use of Zika virus nucleic acid/PCR tests for all other indications, including:
  - A. Symptomatic, non-pregnant members/enrollees
  - B. Routine pre-conception or prenatal screening

[back to top](#)

## Zika Virus Antibody Tests

- I. Zika virus antibody tests are considered **medically necessary** when:
  - A. The member/enrollee is pregnant, **AND**
    - 1. Prenatal ultrasound findings are consistent with congenital Zika virus infection (e.g., microcephaly, ventriculomegaly, or abnormalities of the corpus callosum), **AND**
    - 2. Had a plausible exposure to Zika virus (e.g., traveled to or lives in an area with transmission or had sexual relations with someone who traveled to or lives in an are with transmission), **OR**
  - B. The member/enrollee is 12 months of age or younger, **AND**
    - 1. The member's/enrollee's mother had laboratory evidence of Zika virus infection during pregnancy, **OR**
    - 2. Has [symptoms of congenital Zika virus infection](#), **AND**
      - a) The member's/enrollee's mother had a plausible exposure to Zika virus.
- II. Current evidence does not support the use of Zika virus antibody tests for all other indications, including:
  - A. Symptomatic\* or asymptomatic pregnant members/enrollees
  - B. Symptomatic\*, non-pregnant members/enrollees
  - C. Routine pre-conception or prenatal screening

\*Personal symptoms of Zika virus infection such as fever and conjunctivitis.

[back to top](#)

## NOTES AND DEFINITIONS

1. **Lyme neuroborreliosis** is characterized by cranial or peripheral nerve involvement (facial palsy, radiculoneuropathy), or central nervous system involvement (meningitis/encephalitis).
2. **Lyme arthritis** is characterized by obvious swelling of one or more joints and joint pain with movement.
3. **Congenital Zika virus infection** is a syndrome characterized by a combination of severe microcephaly, sometimes with malformation of the craniofacial bones/skull; decreased brain tissue with a specific pattern of brain damage, including subcortical calcifications; damage to the back of the eye, including macular scarring and focal retinal pigmentary mottling; congenital contractures, such as clubfoot or arthrogryposis; and hypertonia/stiff or rigid posture with restricted movement.

[back to top](#)

## BACKGROUND AND RATIONALE

### Lyme Disease (*Borrelia burgdorferi*) Serum Antibody Tests

*Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR)*

In the 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease, the joint societies make the following recommendations regarding diagnostic testing for Lyme disease. (p. e2-e5)

- Recommend **against** testing in:
  - Asymptomatic patients for exposure to *B. burgdorferi* following an Ixodes spp. tick bite (strong recommendation, moderate-quality evidence),
  - Patients with potential tick exposure in a Lyme disease endemic area who have 1 or more skin lesions compatible with erythema migrans; we recommend clinical

- diagnosis rather than laboratory testing (strong recommendation, moderate quality evidence).
- [X.2] Patients with typical amyotrophic lateral sclerosis, relapsing-remitting multiple sclerosis, Parkinson’s disease, dementia or cognitive decline, or new-onset seizures (strong recommendation, low-quality evidence).
  - Patients presenting with nonspecific magnetic resonance imaging (MRI) white matter abnormalities confined to the brain in the absence of a history of other clinical or epidemiologic support for the diagnosis of Lyme disease (weak recommendation, low-quality evidence).
  - Patients with psychiatric illness (strong recommendation, low-quality evidence)
  - Children presenting with developmental, behavioral or psychiatric disorders (weak recommendation, low-quality evidence).
  - Patients with neurological syndromes other than those listed in recommendation X.1 or X.2 , in the absence of a history of other clinical or epidemiologic support for the diagnosis of Lyme disease (strong recommendation, low-quality evidence).
  - Patients with chronic cardiomyopathy of unknown cause (weak recommendation, low-quality evidence).
- Recommend **serum antibody** testing in:
    - Patients with 1 or more skin lesions suggestive of, but atypical for erythema migrans (weak recommendation, low-quality evidence).
    - Patients with possible Lyme neuroborreliosis involving either the peripheral nervous system (PNS) or central nervous system (CNS).
      - [X.1] Patients presenting with 1 or more of the following acute disorders: meningitis, painful radiculoneuritis, mononeuropathy multiplex including confluent mononeuropathy multiplex, acute cranial neuropathies (particularly VII, VIII, less commonly III, V, VI and others), or in patients with evidence of spinal cord (or rarely brain) inflammation, the former particularly in association with painful radiculitis involving related spinal cord segments, and with epidemiologically plausible exposure to ticks infected with *B burgdorferi* (strong recommendation, moderate-quality evidence).
    - Patients with possible Lyme arthritis (strong recommendation, moderate quality of evidence).
    - Patients with acute myocarditis/pericarditis of unknown cause in an appropriate epidemiologic setting, we recommend testing for Lyme disease (strong recommendation, low quality evidence).

## **Lyme Disease (*Borrelia burgdorferi*) Nucleic Acid/PCR Tests**

*Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR)*

In the 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease, the joint societies recommend serum antibody testing over PCR or culture methods in most clinical scenarios (V.1, IX.1, p. e2-e5).

“...numerous nonserologic methods have been proposed or developed, including nucleic acid amplification tests, culture methods, and antigen detection assays, among others. At present, few nonserologic testing methods are useful or practical for clinical diagnosis, and those that are—primarily nucleic acid amplification tests—are mostly

beneficial as adjunctive tests in select clinical scenarios when 2-tiered serologic testing is positive.”

The joint societies only explicitly recommend PCR testing for Lyme disease in one clinical scenario:

“In seropositive patients for whom the diagnosis of Lyme arthritis is being considered but treatment decisions require more definitive information, we recommend PCR applied to synovial fluid or tissue rather than *Borrelia* culture of those samples (strong recommendation, moderate-quality evidence).” (p. e5)

## **Other Non-covered Lyme Disease Tests**

*Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR)*

“Some commercially available laboratory testing methods, including nonstandard serology interpretation, urine antigen, DNA testing, the use of a lymphocyte transformation test, or quantitative CD57 lymphocyte assay should be avoided for clinical use due to lack of systematic, independent, reproducible validation studies.” (p. e10)



## **Zika Virus Nucleic Acid/PCR Tests**

### *Centers for Disease Control and Prevention (CDC)*

- For asymptomatic pregnant persons living in or with recent travel to the U.S. and its territories, routine Zika virus testing is NOT currently recommended.
- For asymptomatic pregnant individuals with a female reproductive system with recent travel to an area with risk of Zika outside the U.S. and its territories, Zika virus testing of any kind is NOT routinely recommended; if testing is performed, it can be performed via NAAT up to 12 weeks after travel.
- Healthcare providers should test pregnant individuals with a female reproductive system with symptoms of Zika (e.g., fever, rash, headache, arthralgia, conjunctivitis, and muscle pain) if they may have been exposed to Zika through sex without a condom with a person who lives in or traveled to an area with risk of Zika.
- Zika virus NAAT should be performed on maternal serum and urine for pregnant individuals with a female reproductive system who have a fetus with prenatal ultrasound findings consistent with congenital Zika virus infection who live in or traveled to areas with a risk of Zika during pregnancy.
- Zika virus testing should NOT be performed as part of preconception screening.
- Zika testing is NOT currently recommended for symptomatic non-pregnant patients based on the current epidemiology of these viruses.

“Laboratory testing for congenital Zika virus infection is recommended for infants born to mothers with laboratory evidence of Zika virus infection during pregnancy, and for infants who have abnormal clinical findings suggestive of congenital Zika virus syndrome and a maternal epidemiologic link suggesting possible transmission, regardless of maternal Zika virus test results.”

## **Zika Virus Antibody Tests**

### *Centers for Disease Control and Prevention (CDC)*

- Zika virus serologic testing is NOT recommended for symptomatic or asymptomatic pregnant individuals with a female reproductive system.

- Zika virus IgM testing should be performed on maternal serum for pregnant individuals with a female reproductive system who have a fetus with prenatal ultrasound findings consistent with congenital Zika virus infection who live in or traveled to areas with a risk of Zika during pregnancy or had potential sexual exposure to a partner who lives in or traveled to an area with risk of Zika.
- Zika virus testing should NOT be performed as part of preconception screening.
- Zika testing is NOT currently recommended for symptomatic non-pregnant patients based on the current epidemiology of these viruses.

“Laboratory testing for congenital Zika virus infection is recommended for infants born to mothers with laboratory evidence of Zika virus infection during pregnancy, and for infants who have abnormal clinical findings suggestive of congenital Zika virus syndrome and a maternal epidemiologic link suggesting possible transmission, regardless of maternal Zika virus test results.”

[back to top](#)

### Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2023, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT® Codes	Description
0041U	Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM
0042U	Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG
0316U	Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine
86617	Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot)
86618	Antibody; Borrelia burgdorferi (Lyme disease)
86794	Antibody; Zika virus, IgM

CPT® Codes	Description
87475	Infectious agent detection by nucleic acid (DNA or RNA); <i>Borrelia burgdorferi</i> , direct probe technique
87476	Infectious agent detection by nucleic acid (DNA or RNA); <i>Borrelia burgdorferi</i> , amplified probe technique
87662	Infectious agent detection by nucleic acid (DNA or RNA); Zika virus, amplified probe technique

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Policy developed. External specialist reviewed.	11/23	02/24
Added “lab” to policy title. Removed CPT and ICD-10 codes from policy reference table. Added CPT code table and moved the “coding implications” section.	02/24	
Corrected CPT code descriptions and removed 86353.	03/24	
Annual review. Corrected 03/24 revision log to note that 86353 was removed from the CPT table. Added policy number to header. Minor rewording and formatting with no clinical significance. Reworded policy statements from “may be considered medically necessary” to “are considered medically necessary” for the following criteria sections: Lyme Disease ( <i>Borrelia burgdorferi</i> ) Serum Antibody Tests, Lyme Disease ( <i>Borrelia burgdorferi</i> ) Nucleic Acid/PCR Tests, Zika Virus Antibody Tests, and Zika Virus Nucleic Acid/PCR Tests. References updated.	11/24	02/25

## REFERENCES

1. Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Agüero-Rosenfeld ME, Auwaerter PG, Baldwin K, Bannuru RR, Belani KK, Bowie WR, Branda JA, Clifford DB, DiMario FJ Jr, Halperin JJ, Krause PJ, Lavergne V, Liang MH, Meissner HC, Nigrovic LE, Nocton JJJ, Osani MC, Pruitt AA, Rips J, Rosenfeld LE, Savoy ML, Sood SK, Steere AC, Strle F, Sundel R, Tsao J, Vaysbrot EE, Wormser GP, Zemel LS. Clinical

Practice Guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. *Neurology*. 2021 Feb 9;96(6):262-273. doi: 10.1212/WNL.0000000000011151. Epub 2020 Nov 30. Erratum in: *Neurology*. 2021 Feb 9;96(6):296. PMID: 33257476.

2. Testing for Zika. Centers for Disease Control and Prevention. May 15, 2024. Accessed November 08, 2024. <https://www.cdc.gov/zika/testing/>.
3. Zika and Dengue Testing Guidance. Centers for Disease Control and Prevention. May 15, 2024. Accessed November 08, 2024. <https://www.cdc.gov/zika/hc-providers/testing-guidance.html>.

[back to top](#)

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

**Note: For Medicaid members/enrollees**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members/enrollees**, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2023 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.